Pre-Dx Oncology Market Size, Growth Trends and Forecast 2026–2035
According to Shivani Zoting, who specializes in multi-cancer early detection testing, cancer risk assessment and screening solutions, and liquid biopsy and circulating biomarker analysis, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the Pre-Dx oncology market. The global Pre-Dx oncology market size was estimated at USD 6.42 billion in 2025 and is predicted to increase from USD 7.37 billion in 2026 to approximately USD 25.52 billion by 2035, expanding at a CAGR of 14.80% from 2026 to 2035. Her analysis highlights the increasing adoption of companion diagnostic-guided therapies, hereditary cancer risk assessment, predictive oncology biomarkers, and personalized oncology care pathways. The research also examines the competitive strategies of key industry participants, Natera, Illumina, Biocept, Personalis, Roche Diagnostics, and Guardant Health, including shaping the future by enabling earlier cancer risk prediction, advancing personalized cancer prevention strategies, improving predictive treatment planning, and integrating multi-omics into oncology diagnostics in the global Pre-Dx oncology market.
Last Updated : 14 July 2026
Category: Diagnostics
Insight Code: 6334
Format: PDF / PPT / Excel